For example, the DNA methyltransferase inhibitor (DNMTi) 5-azacitidine acted synergistically with cytarabine and etoposide in NSCLC cell lines [8] and the histone deacetylase inhibitor (HDACi) romidepsin enhanced the antitumor effect of erlotinib in NSCLC cell lines of different histology and mutation status, including EGFR- and KRAS-mutants, and wild type cell lines, as well as reduced tumor burden in NCI-H1299 xenograft models [9]. Here, KRAS is linked to non-small cell lung carcinoma.